T 2395/22 of 31.01.2024
- European Case Law Identifier
- ECLI:EP:BA:2024:T239522.20240131
- Date of decision
- 31 January 2024
- Case number
- T 2395/22
- Petition for review of
- -
- Application number
- 16157001.5
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- FORMULATION OF BORONIC ACID COMPOUNDS
- Applicant name
- The United States of America, represented by the
Secretary, Department of Health and Human Services - Opponent name
- Teva Pharmaceutical Industries Ltd
Fresenius Kabi Deutschland GmbH
Pfizer Inc.
LEK Pharmaceuticals d.d.
Synthon BV
PENTAFARMA, Sociedade Técnico-Medicinal, SA
KRKA, d.d., Novo mesto
Zentiva k.s.
Accord Healthcare
Dr. Reddy's Laboratories Ltd./ Betapharm
Arzneimittel GmbH
Generics [UK] Ltd - Board
- 3.3.02
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 123(2)European Patent Convention Art 54European Patent Convention Art 56European Patent Convention Art 83European Patent Convention Art 84Rules of procedure of the Boards of Appeal Art 11Rules of procedure of the Boards of Appeal Art 12(3)Rules of procedure of the Boards of Appeal Art 12(4)Rules of procedure of the Boards of Appeal Art 12(5)Rules of procedure of the Boards of Appeal Art 13(1)Rules of procedure of the Boards of Appeal Art 13(2)
- Keywords
- Novelty with regard to an alleged public prior use
Novelty - obligation to confidentiality
Added subject-matter
Sufficiency of disclosure
Inventive step - Catchword
- -
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The case is remitted to the opposition division
with the order to maintain the patent in amended
form with the claims according to auxiliary
request 5a filed on 30 January 2024 at the oral
proceedings before the board, and a description
to be adapted thereto if appropriate.